Browsing by Author "Taulaigo, A"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Diferenças de Género no Tratamento de Fase Aguda do Acidente Vascular Cerebral IsquémicoPublication . Taulaigo, A; Pedro, B; Mariano, M; Paiva Nunes, AIntroduction: In order to personalize stroke treatment, it is important to know if there are differences between genders in clinical features, acute phase treatment and outcomes. Material and Methods: Longitudinal retrospective study that included patients with ischemic stroke, admitted in a stroke unit during a 30 months period and treated with throm bectomy with or without thrombolysis. The objective was to assess gender differences. Results: Of 594 patients included, 50% were women. At admission, women had higher median age (78 vs 73 years), higher modified Rankin Score (mRS) and higher median Na tional Institutes of Health Stroke Scale (NIHSS). No gender differences were found in treatment type, median time be tween symptoms onset and computed tomography, between computed tomography and thrombolysis and with respect to revascularization success. Disability expressed by mRS and mortality at 3 months were similar between genders. More women had atrial fibrillation (AF) (51% vs 35%), nevertheless, less women with known AF were receiving anticoagulant ther apy before the event, compared to men (38% vs 52%). Discussion: Even if women were older and had worse pre morbid functional status, no gender differences were evident with regard to acute phase treatment efficacy and medium term outcomes. Conclusion: In women, age should not limit acute phase treatment of stroke and decisions should be individualized
- The Impact of COVID-19 on Rare and Complex Connective Tissue Diseases: the Experience of ERN ReCONNETPublication . Talarico, R; Aguilera, S; Alexander, T; Amoura, Z; Antunes, A; Arnaud, L; Avcin, T; Beretta, L; Bombardieri, S; Burmester, G; Cannizzo, S; Cavagna, L; Chaigne, B; Cornet, A; Costedoat-Chalumeau, N; Doria, A; Ferraris, A; Fischer-Betz, R; Fonseca, J; Frank, C; Gaglioti, A; Galetti, I; Grunert, J; Guimarães, V; Hachulla, E; Houssiau, F; Iaccarino, L; Krieg, T; Limper, M; Malfait, F; Mariette, X; Marinello, D; Martin, T; Matthews, L; Matucci-Cerinic, M; Meyer, A; Montecucco, C; Mouthon, L; Müller-Ladner, U; Rednic, S; Romão, V; Schneider, M; Smith, V; Sulli, A; Tamirou, F; Taruscio, D; Taulaigo, A; Terol, E; Tincani, A; Ticciati, S; Turchetti, G; van Hagen, P; van Laar, J; Vieira, A; de Vries-Bouwstra, J; Cutolo, M; Mosca, MDuring the COVID-19 pandemic, the need to provide high-level care for a large number of patients with COVID-19 has affected resourcing for, and limited the routine care of, all other conditions. The impact of this health emergency is particularly relevant in the rare connective tissue diseases (rCTDs) communities, as discussed in this Perspective article by the multi-stakeholder European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET). The clinical, organizational and health economic challenges faced by health-care providers, institutions, patients and their families during the SARS-CoV-2 outbreak have demonstrated the importance of ensuring continuity of care in the management of rCTDs, including adequate diagnostics and monitoring protocols, and highlighted the need for a structured emergency strategy. The vulnerability of patients with rCTDs needs to be taken into account when planning future health policies, in preparation for not only the post-COVID era, but also any possible new health emergencies.